IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Amgen announced Phase 3 DeLLphi-305 interim results showing IMDELLTRA plus AstraZeneca's IMFINZI cut the risk of death by 58% (HR 0.42) as first-line maintenance in extensive-stage small cell lung cancer. Median overall survival rose to 21.1 months versus 12.7 months with durvalumab alone, one-year survival was nearly 80% versus 53%, and progression-free survival more than tripled to 7.4 months versus 1.9 months. The data were presented at ESMO's Presidential Symposium and published in NEJM. Amgen says it is moving with urgency to share the results with regulators worldwide, and updated DeLLphi-303 data showed median OS of 37.9 months in first-line maintenance.
Key figures
- Drug Name
- IMDELLTRA (tarlatamab-dlle)
- Phase Of Trial
- Phase 3
- Orr combo
- 26.4%
- Trial size
- 563
- Orr control
- 4.1%
- Hazard ratio os
- 0.42
- Pfs hazard ratio
- 0.34
- Median os combo months
- 21.1
- Median pfs combo months
- 7.4
- One year survival combo
- nearly 80%
- Median os control months
- 12.7
- Median pfs control months
- 1.9
- One year survival control
- 53%
- Overall survival reduction
- 58%
- Dellphi 303 median os months
- 37.9
- Dellphi 304 median os months
- 13.6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.